Until recently, men with metastatic prostate cancer were commenced on androgen deprivation therapy at diagnosis, followed by sequential lines of treatment with the development of castration resistance. However, the results of recent clinical trials, which revealed that the addition of radiotherapy to the prostate to a dose of 55 to 60 Gy in 20 fractions over 4 weeks in patients with low-volume metastatic hormone-sensitive prostate cancer, in addition to androgen deprivation therapy and another systemic treatment option, either docetaxel, abiraterone, enzalutamide, or apalutamide, has led to a paradigm change in the management of this disease.

中文翻译：

---

转移性前列腺癌原发性治疗的标准护理是什么？

直到最近，患有转移性前列腺癌的男性在诊断时就开始接受雄激素剥夺治疗，随后随着去势抵抗的发展而进行一系列治疗。但是，最近的临床试验结果表明，除了雄激素外，对于患有小批量转移性激素敏感性前列腺癌的患者，在4周内以20个分数在55到60 Gy剂量的基础上对前列腺进行放射治疗剥夺疗法和多西他赛，阿比特龙，enzalutamide或apalutamide的另一种全身性治疗选择已导致这种疾病的治疗方式发生变化。